Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+NSCLC Patients

被引：78
|
作者：
Kowanetz, Marcin [1 ]
Zou, Wei [1 ]
Shames, David [1 ]
Cummings, Craig [1 ]
Rizvi, Naiyer [2 ]
Spira, Alexander [3 ,4 ]
Frampton, Garrett [5 ]
Leveque, Vincent [1 ]
Flynn, Susan [1 ]
Mocci, Simonetta [1 ]
Shankar, Geetha [1 ]
Funke, Roel [1 ]
Ballinger, Marcus [1 ]
Waterkamp, Daniel [1 ]
Chen, Daniel [1 ]
Sandler, Alan [1 ]
Hampton, Garret [1 ]
Amler, Lukas [1 ]
Hegde, Priti [1 ]
Hellmann, Matthew [6 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Columbia Univ, New York, NY USA
[3] US Oncol Res, The Woodlands, TX USA
[4] Virginia Canc Specialists Res Inst, Fairfax, VA USA
[5] Fdn Med, Cambridge, MA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Immunotherapy; mutational load; NSCLC; Biomarkers;
D O I：
10.1016/j.jtho.2016.11.343
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA20.01
引用
收藏
页码：S321 / S322
页数：2
相关论文
共 50 条
  • [31] Role of PD-L1 and Tumor Mutational Burden in NSCLC Immunotherapy
    Peters, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S74 - S74
  • [32] IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups
    Reck, M.
    Kowanetz, M.
    Socinski, M. A.
    Zou, W.
    McCleland, M.
    Yang, N.
    Chavez, Lopez A.
    Spira, A.
    Mazieres, J.
    Braiteh, F.
    Shames, D.
    Sandler, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 239 - 239
  • [33] IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups
    Kowanetz, Marcin
    Socinski, Mark A.
    Zou, Wei
    McCleland, Mark
    Yang, Nancy
    Chavez, Ariel Lopez
    Spira, Alexander
    Mazieres, Julien
    Braiteh, Fadi
    Shames, David
    Sandler, Alan
    Reck, Martin
    CANCER RESEARCH, 2018, 78 (13)
  • [34] IMpower151: Phase III Study of Atezolizumab plus Bevacizumab plus Chemotherapy in 1L Metastatic Nonsquamous NSCLC
    Zhou, C.
    Dong, X.
    Chen, G.
    Wang, Z.
    Wu, X.
    Yao, Y.
    Zhang, Y.
    Cheng, Y.
    Pan, H.
    Zhang, X.
    Cui, J.
    Wang, L.
    Chen, X.
    Li, X.
    Wang, Z.
    Wang, Q.
    He, J.
    Wang, M.
    Yan, I.
    Qian, L.
    An, A.
    Cai, A.
    Wu, Q.
    Ballinger, M.
    Wang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S64 - S65
  • [35] 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+NSCLC (POPLAR)
    Mazieres, J.
    Park, K.
    Lewanski, C.
    Gadgeel, S.
    Fehrenbacher, L.
    Rittmeyer, A.
    Han, J-Y.
    Artal-Cortes, A.
    Braiteh, F.
    Vansteenkiste, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S79 - S79
  • [36] Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients
    Dan Yan
    Yi Chen
    Scientific Reports, 11
  • [37] PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score
    Cho, Yoon Ah
    Lee, Hyunwoo
    Kim, Deok Geun
    Kim, Hyunjin
    Ha, Sang Yun
    Yoon-La Choi
    Jang, Kee-Taek
    Kim, Kyoung-Mee
    CANCERS, 2021, 13 (18)
  • [38] Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients
    Yan, Dan
    Chen, Yi
    SCIENTIFIC REPORTS, 2021, 11 (01) : 9020
  • [39] Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi).
    Dudnik, Elizabeth
    Bshara, Elias
    Grubstein, Ahuva
    Fridel, Ludmila
    Shochat, Tzippy
    Roisman, Laila C.
    Ilouze, Maya
    Rozenblum, Anna B.
    Geva, Smadar
    Zer, Alona
    Rotem, Ofer
    Allen, Aaron
    Peled, Nir
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
    Huang, Richard S. P.
    Carbone, David P.
    Li, Gerald
    Schrock, Alexa
    Graf, Ryon P.
    Zhang, Liangliang
    Murugesan, Karthikeyan
    Ross, Jeffrey S.
    Tolba, Khaled
    Sands, Jacob
    Oxnard, Geoffrey R.
    Spigel, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)
12345